The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Strunina Yu.V.

Association of Specialists in Health Technology Assessment

Petunina N.A.

Sechenov First Moscow State Medical University

Cost-effectiveness and budget impact analysis of fixed combination of alogliptin and pioglitazone in the treatment of type 2 diabetes mellitus

Authors:

Strunina Yu.V., Petunina N.A.

More about the authors

Journal: Medical Technologies. Assessment and Choice. 2023;45(3): 70‑81

DOI: 10.17116/medtech20234503170

Read: 1905 times

Download PDF (RU)
Contact the author
Table of contents

COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF FIXED COMBINATION OF ALOGLIPTIN AND PIOGLITAZONE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS
COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF FIXED COMBINATION OF ALOGLIPTIN AND PIOGLITAZONE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS

To cite this article:

Strunina YuV, Petunina NA. Cost-effectiveness and budget impact analysis of fixed combination of alogliptin and pioglitazone in the treatment of type 2 diabetes mellitus. Medical Technologies. Assessment and Choice. 2023;45(3):70‑81. (In Russ.)
https://doi.org/10.17116/medtech20234503170

Подписка 2026 Медицинские технологии. Оценка и выбор (Medical Technologies. Assessment and Choice)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Is arti­ficial inte­lligence nece­ssary for healthcare system?. Medi­cal Technologies. Asse­ssment and Choice. 2024;(4):40-48
Cost-effectiveness analysis of deno­sumab therapy in adults with solid tumors and bone meta­stases (in Russian healthcare). Medi­cal Technologies. Asse­ssment and Choice. 2024;(4):74-89
Economic issues of medi­cal care for hype­rparathyroidism. Part 1. Primary hype­rparathyroidism. Medi­cal Technologies. Asse­ssment and Choice. 2025;(1):51-61
Cost-effectiveness analysis of bariatric surgery in obese patients. Medi­cal Technologies. Asse­ssment and Choice. 2025;(1):62-75
Pharmacoeconomic analysis of the neta­kimab use for the treatment of psoriasis vulgaris in the health care settings of the Russian Fede­ration. Medi­cal Technologies. Asse­ssment and Choice. 2025;(2):99-105
Economics of hype­rparathyroidism. Part 2 — seco­ndary hype­rparathyroidism. Medi­cal Technologies. Asse­ssment and Choice. 2025;(3):74-82
Cost-effectiveness analysis of triptorelin therapy for patients with prostate cancer in state healthcare system of the Russian Fede­ration. Medi­cal Technologies. Asse­ssment and Choice. 2025;(3):83-92
Abstract:

OBJECTIVE

To determine the optimal therapy regarding cost-effectiveness and budget impact analysis of fixed drug combination (FDC) of alogliptin and pioglitazone in the treatment of adults with diabetes mellitus (DM) type 2.

MATERIAL AND METHODS

Statistical data were obtained from the federal register of patients with DM. Only drug costs were considered in study. We used cost-minimization analysis for scenario 1 (alogliptin + pioglitazone with metformin vs. combination of alogliptin, glibenclamide and metformin) and cost-effectiveness analysis for scenario 2 (alogliptin + pioglitazone with metformin vs. combination of alogliptin and metformin). Time horizon was 3 years in budget impact analysis for current and simulated clinical practice.

RESULTS

FDC alogliptin + pioglitazone with metformin reduced annual treatment cost by 0.4% compared to combination of alogliptin, glibenclamide and metformin. Cost of FDC alogliptin 25 mg +pioglitazone 15 mg with metformin was lower by 15.2% compared to combination of alogliptin with metformin while clinical effectiveness was higher. The incremental cost-effectiveness ratio (ICER) of FDC alogliptin 25 mg + pioglitazone 30 mg with metformin was lower by 62.5% compared to combination of alogliptin with metformin. In simulated clinical practice, FDC alogliptin + pioglitazone with metformin reduce the cost by 731.6 million rubles (lower by 10.7%) throughout 3 years compared to current clinical practice for 109 768 patients.

CONCLUSION

FDC alogliptin+pioglitazone with metformin is either cost-effective or cost-caving option vs compared alternatives.

Keywords:

cost-effectiveness analysis
cost minimization analysis
budget impact
diabetes mellitus type 2
sulfonylureas
dipeptidyl-peptidase 4 inhibitors
thiazolidinediones
sodium-glucose linked transporter-2 inhibitors

Authors:

Strunina Yu.V.

Association of Specialists in Health Technology Assessment

Petunina N.A.

Sechenov First Moscow State Medical University

Received:

11.05.2023

Accepted:

08.06.2023

Close metadata

References:

  1. Salukhov VV, Kovalevskaya E.A. Rethinking the role of pioglitazone in modern diabetology as a cardiorenopro-tective agent. Meditsinskiy sovet. 2022;16(10):10-21. (In Russ.). https://doi.org/10.21518/2079-701x-2022-16-10-10-21
  2. Eldor R, DeFronzo RA, Abdul-Ghani M. In Vivo Actions of Peroxisome Proliferator-Activated Receptors: Glycemic control, insulin sensitivity, and insulin secretion. Diabetes Care. 2013;36(suppl 2):162-174.  https://doi.org/10.2337/dcS13-2003
  3. DeFronzo RA, Inzucchi S, Abdul-Ghani M, Nissen SE. Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes. Diabetes and Vascular Disease Research. 2019;16(2):133-143.  https://doi.org/10.1177/1479164118825376
  4. Erdmann E, Dormandy JA Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. Journal of the American College of Cardiology. 2007;49(17):1772-1780. https://doi.org/10.1016/j.jacc.2006.12.048
  5. Wilcox R, Bousser M-G, Betteridge DJ, Schernthaner G, Pirags V, Kupfer S, et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke. 2007;(3):865-873.  https://doi.org/10.1161/01.STR.0000257974.06317.49
  6. Dedov II, Shestakova MV, Mayorov AYu, Mokrysheva NG, Vikulova OK, Galstyan GR, et al. Standards of specialized diabetes care. 10th edition. Diabetes mellitus. 2021;24(1S):1-148. (In Russ.) https://doi.org/10.14341/DM12802
  7. Klinicheskie rekomendacii. Saharnyj diabet 2-go tipa u vzroslyh. Rossijskaya associaciya endokrinologov; 2019. Accessed June 23, 2023. (In Russ.). https://cr.minzdrav.gov.ru/recomend/290_1
  8. Klinicheskie rekomendacii. Saharnyj diabet 2-go tipa u vzroslyh. Rossijskaya associaciya endokrinologov; 2022. Accessed June 23, 2023. (In Russ.). https://cr.minzdrav.gov.ru/recomend/290_2
  9. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al.; EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. The New England Journal of Medicine. 2013;369(14):77:1327-1335. https://doi.org/10.1056/NEJMoa1305889
  10. Rosenstock J, Inzucchi SE, Seufert J, Fleck PR, Wilson CA, Mekki Q. Initial Combination Therapy with Alogliptin and Pioglitazone in Drug-Naïve Patients with Type 2 Diabetes. Diabetes Care. 2010;33(11):2406-2408. https://doi.org/10.2337/dc10-0159
  11. DeFronzo RA, Burant CF, Fleck P, Wilson C, Mekki Q, Pratley RE. Efficacy and Tolerability of the DPP-4 Inhibitor Alogliptin Combined with Pioglitazone, in Metformin-Treated Patients with Type 2 Diabetes. The Journal of Clinical Endocrinology and Metabolism. 2012;97(5):1615-1622. https://doi.org/10.1210/jc.2011-2243
  12. Bosi E, Ellis GC, Wilson CA, Fleck PR. Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study. Diabetes Obesity and Metabolism. 2011;13(12):1088-1096. https://doi.org/10.1111/j.1463-1326.2011.01463.x
  13. A Study to Determine the Bioequivalence of Alogliptin and Pioglitazone When Administered as Individual Tablets and as Fixed-Dose Combination (FDC)-SYR-322-4833 BL Tablets to Healthy Russian Participants. ClinicalTrials.gov Identifier: NCT03501277. Accessed June 23, 2023. https://clinicaltrials.gov/ct2/show/NCT03501277
  14. Kim JM, Kim SS, Kim JH, Kim MK, Kim TN, Lee SH, et al. Efficacy and Safety of Pioglitazone versus Glimepiride after Metformin and Alogliptin Combination Therapy: A Randomized, Open-Label, Multicenter, Parallel-Controlled Study. Diabetes and Metabolism Journal. 2020;44(1):67-77.  https://doi.org/10.4093/dmj.2018.0274
  15. Peng Y, Chen Sh-H, Liu X-N, Sun Q-Y. Efficacy of different antidiabetic drugs based on metformin in the treatment of type 2 diabetes mellitus: A network meta-analysis involving eight eligible randomized-controlled trials. Journal of Cellular Physiology. 2018;234(3):2795-2806. https://doi.org/10.1002/jcp.27097
  16. Mearns ES, Sobieraj DM, White CM, Saulsberry WJ, Kohn CG, Doleh Yu, et al. Comparative Efficacy and Safety of Antidiabetic Drug Regimens Added to Metformin Monotherapy in Patients with Type 2 Diabetes: A Network Meta-Analysis. PLoS One. 2015;10(4):e0125879. https://doi.org/10.1371/journal.pone.0125879
  17. Efficacy and Safety of Alogliptin Combined with Pioglitazone in Treating Subjects with Type 2 Diabetes Mellitus. ClinicalTrials.gov Identifier: NCT00328627. Accessed June 23, 2023. https://clinicaltrials.gov/ct2/show/NCT00328627
  18. Gosudarstvennyj reestr predel’nyh otpusknyh cen. Accessed June 23, 2023. (In Russ.). https://grls.rosminzdrav.ru/pricelims.aspx
  19. Nedogoda SV, Salasyuk AS, Barykina IN, Lutova VO, Popova EA. A Clinical and Economic Study of the Use of the Fixed-dose Combination of Alogliptin/Pioglitazone in Patients with Type 2 Diabetes Mellitus. Medical care. 2021;4:76-88. (In Russ.). https://doi.org/10.24412/2071-5315-2021-12395
  20. Pratley RE, Reusch JE, Fleck PR, Wilson CA, Mekki Q; Alogliptin Study 009 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Current Medical Research and Opinion. 2009;25(10):2361-2371. https://doi.org/10.1185/03007990903156111
  21. Tan MH, Baksi A, Krahulec B, Kubalski P, Stankiewicz A, Urquhart R, et al. Comparison of Pioglitazone and Gliclazide in Sustaining Glycemic Control Over 2 Years in Patients with Type 2 Diabetes. Diabetes Care. 2005;28(3):544-550.  https://doi.org/10.2337/diacare.28.3.544
  22. Charbonnel B, Schernthaner G, Brunetti P, Matthews DR, Urquhart R, Tan MH, et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia. 2005;48(6):1093-1104. https://doi.org/10.1007/s00125-005-1751-1
  23. Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, D’Agostino RB Sr, et al. Effect of Pioglitazone Compared with Glimepiride on Carotid Intima-Media Thickness in Type 2 Diabetes: A Randomized Trial. JAMA. 2006;296(21):2572-2581. https://doi.org/10.1001/jama.296.21.joc60158
  24. Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, et al.; PERISCOPE Investigators. Comparison of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients with Type 2 Diabetes: The PERISCOPE Randomized Controlled Trial. JAMA. 2008;299(13):1561-1573. https://doi.org/10.1001/jama.299.13.1561
  25. Dedov I, Shestakova M, Massi Benedetti M, Simon D, Pakhomov I, Galstyan G. Prevalence of type 2 diabetes mellitus (T2DM) in the adult Russian population (NATION study). Diabetes Research and Clinical Practice. 2016;19(2):104-112.  https://doi.org/10.1016/j.diabres.2016.02.010
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.